Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 18/20 | 0.49 |
| ▸ | BRD2 | P25440 | 4/20 | 0.49 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.41 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7658898 | 0.79 | BRD4 (0.49) | BRD4BRD2ERN1CREBBP | |
| SCHEMBL30231039 | 0.79 | BRD4 (0.49) | BRD4BRD2ERN1 | |
| SCHEMBL16861646 | 0.79 | ATAD2 (0.50) | BRD4BRD2ERN1CREBBPBRD3 | |
| SCHEMBL9657290 | 0.76 | BRD4 (0.62) | BRD4BRD2ERN1CREBBPBRD3 | |
| SCHEMBL1772573 | 0.74 | BRD4 (0.66) | BRD4BRD2ERN1CREBBPBRD3 | |
| SCHEMBL1502663 | 0.71 | BRD4 (0.41) | BRD4BRD2ERN1CREBBP | |
| SCHEMBL30231173 | 0.70 | BRD4 (0.65) | BRD4BRD2CYP2A6CREBBP | |
| SCHEMBL4211392 | 0.70 | ACHE (0.47) | CYP2A6 | |
| SCHEMBL19564913 | 0.70 | BRD4 (0.48) | BRD4BRD2ERN1CREBBP | |
| SCHEMBL14392676 | 0.70 | CYP2A6 (0.61) | CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230144-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2025-07-17 | — | — | US | disclosed |
| CN-117050074-A | Pyridine bisimidazopyridine compound and preparation method and application thereof | 中国药科大学 | 2023-11-14 | — | — | CN | disclosed |
| US-20230322726-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322726-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| US-20220324836-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-10-13 | — | — | US | disclosed |
| EP-3575288-B1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3575288-B1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-27 | — | — | EP | disclosed |
| US-11008306-B2 | Quinazolines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-18 | — | — | US | disclosed |
| US-11008306-B2 | Quinazolines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200255407-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-13 | — | — | US | disclosed |
| US-20140031345-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031345-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-01-30 | — | — | US | disclosed |
| US-8575184-B2 | Quinazolines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575184-B2 | Quinazolines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575184-B2 | Quinazolines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-05 | — | — | US | disclosed |
| US-20120232068-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTON-MYERS SQUIBB COMPANY (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120232068-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTON-MYERS SQUIBB COMPANY (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120232068-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTON-MYERS SQUIBB COMPANY (US) | 2012-09-13 | — | — | US | disclosed |
| EP-2473487-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | Bristol-Myers Squibb Company (US) | 2012-07-11 | — | — | EP | disclosed |
| WO-2011028741-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324836-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNK4, KCNQ4 | BRD4 830/4885BRD2 3419/4885ERN1 1023/4885 |
| US-20250230144-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNK4, KCNQ4 | BRD4 830/4885BRD2 3419/4885ERN1 1023/4885 |
| US-20200255407-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNK4, KCNQ4 | BRD4 830/4885BRD2 3419/4885ERN1 1023/4885 |
| US-20120232068-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNH3, KCNQ4 | BRD4 874/4885BRD2 3425/4885ERN1 1311/4885 |
| US-11008306-B2 | Quinazolines as potassium ion channel inhibitors | KCNJ4, KCNK4, KCNQ4 | BRD4 830/4885BRD2 3419/4885ERN1 1023/4885 |
| US-20140031345-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNK4, KCNQ4 | BRD4 830/4885BRD2 3419/4885ERN1 1023/4885 |
| US-20230322726-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNK4, KCNQ4 | BRD4 830/4885BRD2 3419/4885ERN1 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.